On the TA front, VIT back to re-test support - break this and low 20s incoming.The FA conundrum is that FY23 results will look good but is it deceiving?When your established competitors (EBO, API, SIG) are operating at 10% Gross Margin to VITs >30% then they're going to come for your lunch.At an annualised cost base of $20m (VIT had $10m below the line expenses for HY) it means $100m revenue is actually loss-making at 10% GM.GM at 10% requires revenue of $200m to B/E.So is it a value trap?
Ann: Vitura Health joining S&P/ASX All Ordinaries Index, page-92
Add VIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $53.55M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 307 | 9.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.3¢ | 981 | 1 |
View Market Depth
| Last trade - 07.20am 27/05/2024 (20 minute delay) ? |
|
|||||
|
Last
9.5¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 9.5¢ | 9.5¢ | 9.5¢ | 69231 | ||
| Last updated 10.22am 27/05/2024 ? | |||||
| VIT (ASX) Chart |
Day chart unavailable